Viewing Study NCT00061633

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 2:51 AM

Ignite Modification Date: 2025-12-26 @ 1:32 AM

Study NCT ID: NCT00061633

Status: COMPLETED

Last Update Posted: 2019-01-16

First Post: 2003-05-30

Is NOT Gene Therapy: False

Has Adverse Events: True

Brief Title: Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

Sponsor: Cumberland Pharmaceuticals

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module Adverse Events Module Baseline Characteristics Module Participant Flow Module